Gareth Neil Brace

This inventor holds 10 USPTO granted patents and 4 published patent applications, plus 2 CIPO patents and 6 EPO patents. Top assignees: Ucbbiopharma Srl, Ucb Biopharma Sprl, Ono Pharmaceutical Co., Ltd.. Active years: 2017-2026.

USPTO Granted Patents = 10 (Patent Applications = 4)

% Patents Active = 70.0

CIPO Patents = 2 (Patent Applications = 7)

EPO Patents = 6 (Patent Applications = 12)

Average Co-Inventor Count = 10.4

ph-index = 3

Forward Citations = 29(Granted Patents)

Location History:

Oxfordshire, GB (2017 - 2020)
Abingdon, GB (2018 - 2022)

Company Filing History:

Ono Pharmaceutical Co., Ltd.

patents

Years Active: 2017-2026

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12679829 - Fused imidazole derivatives as IL-17 modulators (2026-07-14),

2. 12391688 - Imidazopyridine derivatives as IL-17 modulators (2025-08-19),

3. 11472794 - Fused imidazole derivatives as IL-17 modulators (2022-10-18),

4. 11458124 - Spirocyclic indane analogues as IL-17 modulators (2022-10-04),

5. 11052076 - Spirocyclic indolines as IL-17 modulators (2021-07-06),

6. 10717738 - Pyrimidinone and its derivatives inhibiting factor XIa (2020-07-21),

7. 10287299 - Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity (2019-05-14),

8. 10087179 - Fused tricyclic imidazole derivatives as modulators of TNF activity (2018-10-02),

9. 9868749 - Fused imidazole and pyrazole derivatives as modulators of TNF activity (2018-01-16),

10. 9732085 - Pyridinone and pyrimidinone derivatives as factor Xia (2017-08-15),

Title: Gareth Neil Brace: Innovator in IL-17 Modulation

Introduction: Gareth Neil Brace, based in Abingdon, GB, is a notable inventor with a significant contribution to the field of pharmaceutical science, particularly in the modulation of IL-17 activity. With a remarkable six patents to his name, Brace is focused on developing innovative therapeutic solutions for inflammatory and autoimmune disorders.

Latest Patents: Among Brace's latest noteworthy patents are two significant inventions. The first patent describes "Fused imidazole derivatives as IL-17 modulators," which consist of a series of substituted fused bicyclic imidazole derivatives, including benzimidazole derivatives and analogues. These compounds are recognized for their potential in treating various human ailments by modulating human IL-17 activity. The second patent, "Spirocyclic indane analogues as IL-17 modulators," reveals a series of substituted spirocyclic indane derivatives that also serve as potent modulators of human IL-17 activity, promising benefits for the treatment and prevention of similar health conditions.

Career Highlights: Brace has had a fruitful career, working with leading biopharmaceutical companies. His experience includes roles at UCB Biopharma Sprl and UCB Biopharma Srl, where he has contributed to the development of groundbreaking therapies in the field.

Collaborations: Collaborating with esteemed professionals has been a hallmark of Brace's career. He has worked alongside notable coworkers such as Fabien Claude Lecomte and Zhaoning Zhu, fostering an environment of innovation and enhancing the potential impact of their research efforts.

Conclusion: Gareth Neil Brace exemplifies the spirit of innovation in the pharmaceutical industry. With his extensive patent portfolio and dedication to developing therapies for inflammatory and autoimmune disorders, he continues to make a significant impact in improving human health. His collaborations and experience in reputable companies underscore his status as a leading inventor in this critical field.